Literature DB >> 9180137

Tumor-associated lympho-monocytes from neoplastic effusions are immunologically defective in comparison with patient autologous PBMCs but are capable of releasing high amounts of various cytokines.

G Mantovani1, A Macciò, M Pisano, R Versace, P Lai, S Esu, E Massa, M Ghiani, D Dessì, G B Melis, G S Del Giacco.   

Abstract

We studied several in vitro activities of tumor-associated lympho-monocytes (TALMs) and the concentrations of interleukin (IL)-1alpha, IL-1beta, IL-2, IL-4, IL-6, IL-10, tumor necrosis factor (TNF)alpha, interferon (IFN)gamma and soluble IL-2 receptor (slL-2R) in neoplastic effusions and in the serum of advanced stage cancer patients. Comparisons were made with autologous peripheral blood mononuclear cells (PBMCs). Autologous PBMCs were compared with PBMCs from normal subjects used as controls. TALMs were collected from 13 peritoneal and 18 pleural neoplastic effusions, secondary to primary tumors of different sites. After PHA stimulation, concentrations of IL-1alpha, IL-1beta and TNF alpha in culture media of TALMs both from peritoneal and pleural effusions were lower than those of autologous PBMCs and, similarly, concentrations of IL-4 and IL-10 in culture media of TALMs from peritoneal effusions were lower than those of autologous PBMCs, whereas concentrations of IL-4 and IL-10 in culture media of TALMs from pleural effusions were in the same range as those of autologous PBMCs. On the contrary, IL-2, IL-6 and IFN gamma amounts (only from pleural effusions) were significantly higher. IL-1alpha, IL-1beta, IL-2, IL-6 and TNF alpha production from patient PBMCs was lower than that of control PBMCs, whereas production of IL-4, IL-10 and IFN gamma was higher than that of control PBMCs. Both in peritoneal and in pleural effusions concentrations of IL-1alpha, IL-1beta and IL-4 were not different from those measured in autologous serum, whereas those of IL-6, IL-10, TNF alpha, IFN gamma and sIL-2R were significantly higher. The amounts of IL-2 in pleural effusions were not different from those of autologous serum, but in peritoneal effusions they were higher than those of autologous serum. The amounts of IL-1alpha, IL-1beta, IL-2, IL-6, TNF alpha and sIL-2R were higher in patient than in control sera, whereas those of IL-4, IL-10 and IFN gamma were in the same range in patient and in control sera. Cell cycle analysis of cultured TALMs and PBMCs (from 3 patients) showed a significant accumulation of TALMs in the non-cycling G0/G1 cell population compared with autologous PBMCs.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9180137     DOI: 10.1002/(sici)1097-0215(19970529)71:5<724::aid-ijc6>3.0.co;2-t

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

Review 1.  Microenvironmental regulation of tumor progression and metastasis.

Authors:  Daniela F Quail; Johanna A Joyce
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

2.  Oxidative dna damage of lymphocytes in peripheral blood and ascites in cancer patients.

Authors:  J Wang; S S Xing; S B Guo; W Jin; W Zhang
Journal:  Curr Oncol       Date:  2012-07       Impact factor: 3.677

Review 3.  The role of interleukin-6 in the evolution of ovarian cancer: clinical and prognostic implications--a review.

Authors:  Antonio Macciò; Clelia Madeddu
Journal:  J Mol Med (Berl)       Date:  2013-09-21       Impact factor: 4.599

4.  Neoplastic fever in patients with bone and soft tissue sarcoma.

Authors:  Tomoki Nakamura; Akihiko Matsumine; Takao Matsubara; Kunihiro Asanuma; Akihiro Sudo
Journal:  Mol Clin Oncol       Date:  2016-09-21

Review 5.  Oxidative stress in Fanconi anemia hematopoiesis and disease progression.

Authors:  Wei Du; Zsuzsanna Adam; Reena Rani; Xiaoling Zhang; Qishen Pang
Journal:  Antioxid Redox Signal       Date:  2008-11       Impact factor: 8.401

6.  Immunohistochemical staining of tumor necrosis factor-α and interleukin-10 in benign and malignant ovarian neoplasms.

Authors:  Millena Prata Jammal; Allison Araújo DA Silva; Agrimaldo Martins Filho; Eliângela DE Castro Côbo; Sheila Jorge Adad; Eddie Fernando Candido Murta; Rosekeila Simões Nomelini
Journal:  Oncol Lett       Date:  2014-12-08       Impact factor: 2.967

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.